 |
 |

Subclinical Thyroid Disease and Cardiovascular Disease
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
To the Editor: In their Scientific Review and Clinical Applications article on subclinical thyroid disease,1 Dr Surks and colleagues stated that although several studies suggested that levothyroxine therapy will reduce total and low-density lipoprotein (LDL) cholesterol levels in patients with subclinical hypothyroidism,2 this finding had not been confirmed in randomized placebo-controlled trials, including a study for which 2 of us were authors.3 This is not accurate. In our study, patients with subclinical hypothyroidism had total and LDL cholesterol levels significantly higher than controls, which correlated with baseline serum thyrotropin (TSH) levels. Six months of levothyroxine therapy resulted in a significant decrease of both total and LDL cholesterol concentrations proportional to the baseline levels (8.0% and 10.2%, respectively). Although greater improvement in total and LDL cholesterol levels was detected in patients with TSH levels of more than 6.0 mIU/L (11.3% and 15.6%, respectively), reduction in both total and LDL cholesterol . . . [Full Text of this Article]
Nadia Caraccio, MD;
Angela Dardano, MD;
Fabio Monzani, MD
fmonzani@med.unipi.it Department of Internal Medicine University of Pisa School of Medicine Pisa, Italy
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLES
Subclinical Thyroid Disease and Cardiovascular DiseaseReply
Martin I. Surks
JAMA. 2005;293(9):1060.
EXTRACT
| FULL TEXT
Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management
Martin I. Surks, Eduardo Ortiz, Gilbert H. Daniels, Clark T. Sawin, Nananda F. Col, Rhoda H. Cobin, Jayne A. Franklyn, Jerome M. Hershman, Kenneth D. Burman, Margo A. Denke, Colum Gorman, Richard S. Cooper, and Neil J. Weissman
JAMA. 2004;291(2):228-238.
ABSTRACT
| FULL TEXT
|